Novo Nordisk A/S (NVO)

90.75
+2.53(+2.87%)
After Hours
90.75
0.00(0.00%)
- Real-time Data
  • Volume:
    1,653,663
  • Bid/Ask:
    86.18/91.00
  • Day's Range:
    89.29 - 90.86

NVO Overview

Prev. Close
88.22
Day's Range
89.29-90.86
Revenue
20.66B
Open
89.62
52 wk Range
63.22-90.86
EPS
2.92
Volume
1,653,663
Market Cap
205.33B
Dividend (Yield)
1.44
(1.63%)
Average Vol. (3m)
907,795
P/E Ratio
31.14
Beta
0.43
1-Year Change
-23.44%
Shares Outstanding
2,272,064,000
Next Earnings Date
Nov 03, 2021
What is your sentiment on Novo Nordisk A/S?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S News

Novo Nordisk A/S Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Novo Nordisk A/S Company Profile

Novo Nordisk A/S Company Profile

Employees
45157

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Read More
  • NVO WILL BUY ORMP AT 30 $
    0
    • and Gals..! :D
      0
      • Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
        1
        • Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
          0
      • Very good long term investment
        0
        • Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
          0
          • My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.